Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia

被引：13

作者：

Percival, Mary-Elizabeth M. ^{[1
,2
]}

Estey, Elihu H. ^{[1
,2
]}

机构：

[1] Univ Washington, Dept Med, Div Hematol, 825 Eastlake Ave E,MS CE3-300, Seattle, WA 98109 USA

[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA

来源：

CANCER | 2019年 / 125卷 / 18期

关键词：

acute myeloid leukemia (AML); clinical trials; complete remission; measurable residual disease (MRD); HEMATOPOIETIC-CELL TRANSPLANTATION; COMPLETE REMISSION; PROGNOSTIC IMPACT; GEMTUZUMAB OZOGAMICIN; RISK STRATIFICATION; DIRECTED THERAPY; IMPROVE OUTCOMES; FLOW-CYTOMETRY; AML; RELAPSE;

D O I：

10.1002/cncr.32354

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with acute myeloid leukemia (AML) who achieve a morphologic complete remission still can have measurable residual disease (MRD) detected by multiparametric flow cytometry, molecular methods, or cytogenetics. Such patients with MRD have a high risk of disease recurrence over a short timeframe, but optimal treatment strategies are unknown. Outcomes with conventional treatment, including allogeneic hematopoietic cell transplantation, are worse than those for patients without MRD. Herein, the authors review current strategies, including novel clinical trials, targeted toward patients with MRD.

引用

页码：3121 / 3130

页数：10

共 49 条

[21] Gemtuzumab Ozogamicin Can Reduce Minimal Residual Disease in Patients With Childhood Acute Myeloid Leukemia [J].

O'Hear, Carol ;

Inaba, Hiroto ;

Pounds, Stanley ;

Shi, Lei ;

Dahl, Gary ;

Bowman, W. Paul ;

Taub, Jeffrey W. ;

Pui, Ching-Hon ;

Ribeiro, Raul C. ;

Coustan-Smith, Elaine ;

Campana, Dario ;

Rubnitz, Jeffrey E. .

CANCER, 2013, 119 (22) :4036-4043

[22] Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias [J].

Ommen, Hans Beier ;

Schnittger, Susanne ;

Jovanovic, Jelena V. ;

Ommen, Ingrid Beier ;

Hasle, Henrik ;

Ostergaard, Mette ;

Grimwade, David ;

Hokland, Peter .

BLOOD, 2010, 115 (02) :198-205

[23] MRD in AML: does it already guide therapy decision-making? [J].

Ossenkoppele, Gert ;

Schuurhuis, Gerrit Jan .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, :356-365

[24] Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia [J].

Othus, M. ;

Wood, B. L. ;

Stirewalt, D. L. ;

Estey, E. H. ;

Petersdorf, S. H. ;

Appelbaum, F. R. ;

Erba, H. P. ;

Walter, R. B. .

LEUKEMIA, 2016, 30 (10) :2080-2083

[25] Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial [J].

Platzbecker, U. ;

Wermke, M. ;

Radke, J. ;

Oelschlaegel, U. ;

Seltmann, F. ;

Kiani, A. ;

Klut, I-M ;

Knoth, H. ;

Roellig, C. ;

Schetelig, J. ;

Mohr, B. ;

Graehlert, X. ;

Ehninger, G. ;

Bornhaeuser, M. ;

Thiede, C. .

LEUKEMIA, 2012, 26 (03) :381-389

[26] Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial [J].

Platzbecker, Uwe ;

Middeke, Jan Moritz ;

Sockel, Katja ;

Herbst, Regina ;

Wolf, Dominik ;

Baldus, Claudia D. ;

Oelschlagel, Uta ;

Mutherig, Anke ;

Fransecky, Lars ;

Noppeney, Richard ;

Bug, Gesine ;

Goetze, Katharina S. ;

Kraemer, Alwin ;

Bochtler, Tilmann ;

Stelljes, Matthias ;

Groth, Christoph ;

Schubert, Antje ;

Mende, Marika ;

Stoelzel, Friedrich ;

Borkmann, Christin ;

Kubasch, Anne Sophie ;

von Bonin, Malte ;

Serve, Hubert ;

Haenel, Mathias ;

Duehrsen, Ulrich ;

Schetelig, Johannes ;

Roellig, Christoph ;

Kramer, Michael ;

Ehninger, Gerhard ;

Bornhaeuser, Martin ;

Thiede, Christian .

LANCET ONCOLOGY, 2018, 19 (12) :1668-1679

[27] Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia [J].

Pollyea, Daniel A. ;

Stevens, Brett M. ;

Jones, Courtney L. ;

Winters, Amanda ;

Pei, Shanshan ;

Minhajuddin, Mohammad ;

D'Alessandro, Angelo ;

Culp-Hill, Rachel ;

Riemondy, Kent A. ;

Gillen, Austin E. ;

Hesselberth, Jay R. ;

Abbott, Diana ;

Schatz, Derek ;

Gutman, Jonathan A. ;

Purev, Enkhtsetseg ;

Smith, Clayton ;

Jordan, Craig T. .

NATURE MEDICINE, 2018, 24 (12) :1859-+

[28] Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML [J].

Puckrin, Robert ;

Atenafu, Eshetu G. ;

Claudio, Jaime ;

Chan, Steven M. ;

Gupta, Vikas ;

Maze, Dawn ;

McNamara, Caroline J. ;

Minden, Mark D. ;

Schuh, Andre ;

Murphy, Tracy ;

Sibai, Hassan ;

Yee, Karen W. L. ;

Stockley, Tracy L. ;

Kamel-Reid, Suzanne ;

Schimmer, Aaron D. .

BLOOD, 2018, 132

[29] Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial [J].

Rollig, Christoph ;

Serve, Hubert ;

Huettmann, Andreas ;

Noppeney, Richard ;

Mueller-Tidow, Carsten ;

Krug, Utz ;

Baldus, Claudia D. ;

Brandts, Christian H. ;

Kunzmann, Volker ;

Einsele, Hermann ;

Kraemer, Alwin ;

Schaefer-Eckart, Kerstin ;

Neubauer, Andreas ;

Burchert, Andreas ;

Giagounidis, Aristoteles ;

Krause, Stefan W. ;

Mackensen, Andreas ;

Aulitzky, Walter ;

Herbst, Regina ;

Haenel, Mathias ;

Kiani, Alexander ;

Frickhofen, Norbert ;

Kullmer, Johannes ;

Kaiser, Ufrich ;

Link, Hartmut ;

Geer, Thomas ;

Reiche, Albert ;

Junghanss, Christian ;

Repp, Roland ;

Heits, Frank ;

Duerk, Heinz ;

Hase, Jana ;

Klut, Ina-Maria ;

Illmer, Thomas ;

Bornhaeuser, Martin ;

Schaich, Markus ;

Parmentier, Stefani ;

Goerner, Martin ;

Thiede, Christian ;

von Bonin, Malte ;

Schetelig, Johannes ;

Kramer, Michael ;

Berdel, Welfgang E. ;

Ehninger, Gerhard .

LANCET ONCOLOGY, 2015, 16 (16) :1691-1699

[30] Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial [J].

Rubnitz, Jeffrey E. ;

Inaba, Hiroto ;

Dahl, Gary ;

Ribeiro, Raul C. ;

Bowman, W. Paul ;

Taub, Jeffrey ;

Pounds, Stanley ;

Razzouk, Bassem I. ;

Lacayo, Norman J. ;

Cao, Xueyuan ;

Meshinchi, Soheil ;

Degar, Barbara ;

Airewele, Gladstone ;

Raimondi, Susana C. ;

Onciu, Mihaela ;

Coustan-Smith, Elaine ;

Downing, James R. ;

Leung, Wing ;

Pui, Ching-Hon ;

Campana, Dario .

LANCET ONCOLOGY, 2010, 11 (06) :543-552

← 1 2 3 4 5 →